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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the benefits and harms of modified dietary fat intake in the treatment of gallstone disease.
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B A C K G R O U N D
Gallstone disease, also known as cholelithiasis, is characterised
as hard deposits or stones in the gallbladder and biliary tract. A
normally functioning gallbladder stores bile and releases it into
the small intestine when it is needed for digestion. Gallstones can
develop if the bile contains too much cholesterol or bilirubin, if the
gallbladder is dysfunctional, or if the release of bile is impaired. The
type of gallstone is defined by its composition and can be divided
into two main groups: those that are cholesterol-rich, which are the
form predominantly found in people with 'Western' lifestyles; and
those that are composed predominantly of bile pigments (Jones
2020).
Recognised risk factors for the disease include female sex,
hereditary predisposition, increasing age and body mass index
(BMI), rapid weight loss, diabetes, and gastrointestinal and biliary
factors, including infection. Prevalence of gallstones varies with
the sex and age of the population studied and the diagnostic
criteria used; published studies indicate prevalence of between
0.8% and 64.1% (Everhart 2002; Ehlin 2003). Prevalence of
cholesterol gallstones is generally considered to be increasing
as a consequence of nutritional and lifestyle changes, ageing
populations, the increasing global prevalence of obesity, and
improved diagnostic capabilities (Stinton 2010; Aune 2016).
Gallstones can be diagnosed on the basis of medical history, clinical
findings, and imaging. The most appropriate imaging method is
abdominal ultrasound imaging, which is supported by high-quality
evidence (EASL 2016).
Currently, cholecystectomy, predominantly via a laparoscopic
approach, is the standard treatment for symptomatic
cholecystolithiasis (Keus 2006; EASL 2016). It is estimated that more
than 500,000 people undergo cholecystectomy for symptomatic
gallstones each year in the USA (Olsen 1991; NIH 1993; Roslyn 1993).
Description of the condition
Some people who develop gallstone disease may have no
symptoms at all, while others may experience severe abdominal
pain (biliary colic), nausea, and vomiting. It is estimated that 2%
to 4% of people with gallstones develop symptoms each year
(Gurusamy 2014). People with gallstone symptoms have a risk of
approximately 25% of developing complications over 10 to 20 years
(Tait 1995), which is higher than the complication risk of those who
are asymptomatic (Tait 1995; Festi 2010). The risk of complications
is also influenced by the location of gallstones, as those lodged
in the common bile duct carry a higher risk of complications of
approximately 20% over five years (Tait 1995). Symptoms include
cholecystitis, and less commonly, obstructive jaundice, cholangitis,
acute pancreatitis, and gangrene of the gallbladder.
Description of the intervention
Symptomatic gallstone disease is oIen treated by surgically
removing the gallbladder (cholecystectomy), most commonly
undertaken laparoscopically (Keus 2006; EASL 2016). While this
may be common practice, medical management can also be a first-
line treatment. This can include dissolving the gallstones with drug
therapy; for example, with ursodeoxycholic acid (Boerlage 2017).
However, traditionally, restricting dietary fat intake was used to
reduce the pain associated with gallbladder contractions, rather
than dissolving the gallstones. A survey of dietary practice in
the UK indicated that people were regularly advised to restrict
fat to manage their gallstone disease, but at that time, there
was limited empirical evidence to justify this approach (Madden
1992). Mogadam and colleagues also reported that dietary fat
restriction was a frequent method of management, but contested
the therapeutic relevance of this form of dietary management
(Mogadam 1984).
Currently, sources of information for people with gallstone disease
advise adherence to low fat, low cholesterol diets, or both (British
Liver Trust 2018; Healthline 2018; Patient 2020). This suggests that
a dietary intervention is still current treatment for this disease,
even though the rationale appears to be uncertain. We consider
'treatment' to mean something that is designed to play a role in
the management of the condition rather than to prevent gallstones
from forming. A preliminary review of the literature indicates
that there is no published evidence of the benefits of a low fat
diet compared with standard diet. However, with the increasing
prevalence of obesity, there is evidence that people with obesity
who are advised to follow weight-reducing diets that incorporate
a very low fat diet may be more likely to develop gallstones (Festi
2000), and that diets higher in fat may reduce gallstone risk in
adults losing weight (Stokes 2014). We do not anticipate that
specific populations would experience diKerent outcomes from
interventions.
How the intervention might work
The rationale for restricting or modifying dietary fat in the
treatment of gallstone disease has two putative mechanisms.
First, as dietary fat is a potent stimulator of gallbladder
contraction, dietary fat may provoke or exacerbate post-prandial
pain. Therefore, hypothetically, restricting dietary fat might reduce
pain. However, the gallbladder also contracts spontaneously
(Behar 1989), and in response to an intake of mixed meals,
protein (Hopman 1985), or cephalic stimulation (Hopman 1987).
Furthermore, if restricting dietary fat does lead to a reduction in
gallbladder contractions and emptying, it may also increase the risk
of gallstone deposition, as lithogenic bile would be retained longer
in the gallbladder, thus potentially exacerbating the problem. This
mechanism is relevant for gallstones composed of cholesterol and
of pigment.
Second, reducing total dietary fat, and particularly saturated
fat, leads to a reduction in plasma cholesterol. Lower plasma
cholesterol levels may be accompanied by a parallel reduction
in biliary cholesterol concentration, which would reduce the
precipitation of cholesterol in the bile and decrease the risk of
forming cholesterol-rich gallstones (Mendez-Sanchez 2007). This
potential mechanism is complicated by the fact that circulating
cholesterol levels are more influenced by endogenous cholesterol
synthesis than by the intake of dietary cholesterol per se (Lecerf
2011). If this mechanism provides a rationale for the potential
treatment of cholesterol-rich stones, it is unlikely to be relevant to
the management of stones composed predominantly of pigment.
Why it is important to do this review
Dietary advice to restrict or modify fat intake, which is currently
promoted as treatment for people with gallstones, does not appear
to be based on rationalised evidence. While there are general
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health benefits associated with avoiding excessive dietary fat,
i.e. reduced risk of obesity and cardiovascular disease, current
UK guidelines indicate that specific benefits of a modified diet
for the treatment of gallstone disease need clarification (NICE
2014). First, it is important to determine if there are benefits from
modified fat intake, or detrimental eKects from reduced gallbladder
emptying. Second, it would be informative to quantify the amount
of fat reduction needed, so that tailored advice could be given, in
particular to the minority of people with gallstone disease who are
underweight and potentially at risk of malnutrition. We could find
no meta-analysis or systematic reviews assessing this topic.
This review will systematically examine the evidence for the dietary
management of gallstone disease, clarify the therapeutic benefits
and potential risks of dietary interventions as an interim measure
while waiting for surgical intervention, and identify the need for
future research.
O B J E C T I V E S
To assess the benefits and harms of modified dietary fat intake in
the treatment of gallstone disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials assessing benefits
and harms of any type of modification of dietary fat intake
versus standard care (i.e. no specific additional or alternative
intervention), or versus any other type of dietary modification.
We will include cluster-randomised clinical trials and cross-over
randomised clinical trials, but will only use the data from the first
trial period of the latter design to avoid residual eKects from the
intervention (Higgins 2021a; Higgins 2021b). We will not include
quasi-randomised clinical trials, i.e. where a quasi-random method
of allocation has been used (alternation, date of birth, or case
record number), or observational studies unless they report harms.
We will not specifically search for such observational studies for
inclusion in this review, which is a known limitation of our review
in terms of adverse events. We are aware that the decisions
to not search systematically for all observational studies and to
extract data on harms might bias our review towards assessment
of benefits and might overlook certain harms such as late or
rare harms. If we demonstrate benefits from modified dietary fat
intake in this systematic review of randomised clinical trials, then a
systematic review of the harms of this intervention in observational
studies ought to be undertaken (Storebø 2018).
Types of participants
Inclusion criteria
We will include participants with gallstone disease (cholesterol,
pigment, or mixed) diagnosed using ultrasound, who are receiving
a dietary intervention which may or may not have the primary
purpose of treating gallstones.
Participants can be male or female, and of any age or ethnic origin.
Exclusion criteria
We will exclude participants who have been diagnosed with
another condition that may compromise dietary fat tolerance,
e.g. cholestatic liver disease, short bowel, intestinal failure, or
pancreatic insuKiciency.
We will exclude groups of participants that include people with and
without gallstones if these cannot be analysed separately.
Types of interventions
Experimental intervention
The experimental intervention is any type or level of modification
of dietary fat intake, providing that it diKers from the comparison
group.
The experimental intervention might include, for example:
restriction of total fat intake, modification of cholesterol intake,
long chain fatty acid intake, saturated fat intake, plants sterols and
stanols, and fat from specific sources, such as dairy fat or animal fat.
Some trials may have diKerent modes of delivery to the
gastrointestinal tract, e.g. oral or enteral nutrition, both of which we
will include. However, we will exclude trials where the intervention
or comparison is exclusively parenteral, i.e. does not include oral or
enteral intake.
We will include trials that test the eKects of the frequency and
timing of dietary fat intake.
We will also include trials that have three or more dietary
interventions, as long as one of the groups contains a form of
dietary modification as described above, and we will take account
of additional groups during the analysis, as described below (Unit
of analysis issues).
We will include trials that include a co-intervention, such as drugs
or other dietary (non-fat) components, e.g. psyllium or soluble fibre
(Ganji 1994; Theuwissen 2008), providing that the trial groups have
received the same proportion of drug or other dietary (non-fat)
components in the intervention, or if there are separate groups in
the trial in which there have been no drug or other dietary (non-fat)
component co-interventions.
Control intervention (comparison group)
We will compare modified dietary fat intake against standard
care (i.e. no specific additional or alternative intervention), or
against any other type of dietary modification excluding dietary fat,
providing that fat intake can be quantified in both study groups.
This could be quantified as either grams of fat per day or per test
meal, or expressed as percentage energy. We will analyse studies
where the control intervention is standard care (no additional or
alternative intervention) separately from those where the control
intervention is any other type of dietary modification excluding
dietary fat.
Types of outcome measures
We will collect data with their ranges of follow-up, and will assess
all outcomes at the longest follow-up.
Primary outcomes
• All-cause mortality, at longest follow-up.
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• Proportion of participants with serious adverse events at longest
follow-up. Depending on the availability of data, we will attempt
to classify adverse events as serious or non-serious. We will
record how serious adverse events were assessed in each study
according to Good Clinical Practice (GCP). We will define a
serious adverse event according to the International Conference
on Harmonization (ICH) Guidelines for GCP, as "any untoward
medical occurrence that results in death, is life-threatening,
requires inpatient hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, or is a congenital anomaly or birth defect" (ICH-
GCP 1997). This reflects the description used in other Cochrane
Review protocols (Markotic 2020). We will specifically report on
cholecystitis, pancreatitis, and cholangitis. We will consider any
other adverse events to be non-serious (that is, any medical
occurrence, not necessarily having a causal relationship with the
treatment, but leading to a dose reduction or discontinuation of
the treatment).
• Health-related quality of life, assessed using validated tests (e.g.
the five-dimension EuroQol (EQ-5D) scale (EuroQol Group 1990),
or the 36-item Short Form (SF-36) tool (Garratt 1993), at longest
follow-up.
Secondary outcomes
• Proportion of participants without dissolution or reduction in
size of gallstones, at longest follow-up.
• Proportion of participants admitted to hospital for gallstone-
related complications, at longest follow-up.
• Proportion of participants subjected to a surgical intervention,
at longest follow-up.
• Proportion of participants with non-serious adverse events, at
longest follow-up.
We will not exclude studies that do not report the pre-specified
outcomes of the study authors, and if studies do not report
important outcomes, we will note this and report it in the
Implications for Research part of this review's Conclusions.
Search methods for identification of studies
Electronic searches
We will identify trials by searching the Cochrane Hepato-
Biliary Group Controlled Trials Register (maintained and searched
internally by the CHBG Information Specialist via the Cochrane
Register of Studies Web), the Cochrane Central Register of
Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE
Ovid, Embase Ovid, LILACS (Latin American and Caribbean Health
Science Information database) (Bireme), Science Citation Index
Expanded (Web of Science), and Conference Proceedings Citation
Index - Science (Web of Science; (Royle 2003)). Appendix 1 gives the
preliminary search strategies with the expected time spans of the
searches. We will include reports of trials in languages other than
English, providing we can obtain a reliable translation, which we
will do following Cochrane recommendations (Higgins 2021a).
Searching other resources
Two review authors (AMM and AC) will identify other relevant
trials by searching reference lists of identified trials and
conference proceedings. We will also search online trial
registries, such as ClinicalTrial.gov (clinicaltrials.gov/), European
Medicines Agency (EMA; www.ema.europa.eu/ema/), World
Health Organization International Clinical Trial Registry Platform
(ictrptest.azurewebsites.net/Default.aspx), the Food and Drug
Administration (FDA; www.fda.gov), and pharmaceutical company
sources, for ongoing or unpublished trials. We will check
documents that cite our protocol. We will search for grey literature
in the System for Information on Grey Literature in Europe
OpenGrey (www.opengrey.eu).
Data collection and analysis
We will perform the review following Cochrane recommendations
(Higgins 2021a). We will use Review Manager Web for the analyses
(RevMan web 2020). In case of disagreements between AMM and
AC that cannot be resolved by discussion, DT or NS will serve as
arbitrator.
Selection of studies
Two review authors (AMM and AC) will independently review the
titles and abstracts of trials identified by the electronic searches
and agree on potential publications. We will retrieve the full
text of all apparently relevant trials. Two review authors will
independently assess the full text of potential trials for inclusion
in the review according to the prespecified criteria. We will resolve
diKerences in opinion by discussion. In the event that we cannot
resolve diKerences, we will ask a third author (DT or NS) to provide
an opinion. We will keep a record of all included and excluded trials
that are selected from the title review.
Data extraction and management
We will design a data collection form and pilot this on one study.
We will then use the adapted form to record study characteristics
from the included trials on design, interventions, participants,
and outcomes as described in the Criteria for considering studies
for this review section above. Two review authors (AMM and AC)
will independently extract the data. We will resolve diKerences in
extracted results by discussion, and in the event of no agreement,
we will ask a third author (DT or NS) to provide an opinion.
Assessment of risk of bias in included studies
Two review authors (DT and AMM) will independently assess the
risk of bias in each of the included trials. We will resolve any
disagreements by consensus or by consulting another review
author (NS or AC) if required. We will assess risk of bias (RoB)
using the RoB 2 tool (Sterne 2019; Higgins 2021c), according to the
domains defined in the Methodological Expectations of Cochrane
Intervention Reviews (MECIR) protocol reporting standard 27
(Higgins 2021d) and methodological studies (Schulz 1995; Moher
2009; Kjaergard 2001; Wood 2008; Savović 2012a; Savović 2012b;
Savović 2018). We will use the RoB 2 tool when assessing the eKect
of assignment to the intervention (Sterne 2019; Higgins 2021c). In
order to do this, we will perform analysis based on the intention-
to-treat (ITT) principle which includes all randomised participants
irrespective of the interventions that participants actually received.
Where we can obtain the original data from the investigators, we
will perform multiple imputation using the methods described by
Jakobsen 2017.
We will use the following five domains to assess bias in the
individually randomised trials, including cross-over trials (Higgins
2021b; Higgins 2021c):
• bias arising from the randomisation process;
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• bias due to deviations from intended interventions;
• bias due to missing outcome data;
• bias in measurement of an outcome;
• bias in selection of the reported result.
For trials that allocated clusters of individuals, we will include
a sixth domain specific to the trial design to assess bias, i.e.
bias arising from the timing of identification and recruitment
of individual participants in relation to timing of randomisation
(Eldridge 2016).
We will assign one of the three levels of judgement to an overall
rating as follows (Naing 2020):
• low risk of bias: the trial is judged to be at low risk of bias for all
domains for this result;
• some concerns: the trial is judged to raise some concerns in at
least one domain for this result, but is not at high risk of bias for
any of the remaining domains;
• high risk of bias: the trial is judged to be at high risk of bias in at
least one domain for this result, or the study is judged to have
some concerns for multiple domains in a way that substantially
lowers confidence in the result.
The overall risk of bias judgement is the same as for the individual
domains, such as low risk of bias, some concerns, or high risk of
bias. Judging a result to be at a particular level of risk of bias for an
individual domain implies that the result has an overall risk of bias
at least this severe.
We will use the RoB 2 MicrosoI Excel tool to store the data until they
can be published in an online repository, which will allow inclusion
of the rationale for each judgement for each signalling question for
each study for each result (RoB 2 Tool; Sterne 2019).
The overall risk of bias assessments will feed into one domain of
the GRADE approach for assessing certainty of a body of evidence
(Schünemann 2021).
We will focus on results of the trials that contribute information that
users of the review will find most useful. We will, therefore, present
the following outcomes in the summary of findings tables:
• all-cause mortality;
• proportion of participants with serious adverse events;
• health-related quality of life.
We will not modify the RoB 2 tool, with the exception of the domains
for assessing bias for cluster-randomised clinical trials.
Measures of treatment e9ect
We will analyse dichotomous data using risk ratios, converting odds
ratios to risk ratios using the standard formula. We will report
risk ratios with 95% confidence intervals (CIs). We will analyse
outcomes measured as continuous data, such as patient-reported
data that uses a 100 mm visual analogue scale (Walker 2020), using
means and mean diKerences with their corresponding standard
deviations and standard errors, and report these with 95% CIs.
We will consider baseline data and data from all available post-
intervention time points.
Unit of analysis issues
We will consider randomised clinical trials that have a parallel-
group design, in which participants are intended to remain in the
group to which they were initially assigned. We will consider trials
with two or multiple arms eligible.
If trials have non-standard designs or multiple intervention groups,
we will consider for each study whether the groups of individuals
were randomised together to the same intervention (e.g. cluster-
randomised trials; (Higgins 2021b)). We will consider the impact on
the analysis of these clustering, matching, or other non-standard
design features of the included trials using MECIR Box 6.2.a and
MECIR Box 6.2.b (Higgins 2021d).
We will also consider whether individuals underwent more than
one intervention (e.g. cross-over trials or simultaneous treatment
on each individual), or whether there were multiple observations
for the same outcome (e.g. repeated measurements at diKerent
time points) (Higgins 2021b).
Dealing with missing data
We will try to find data on all participants who were randomised,
so that we can undertake intention-to-treat analyses, which will
include all participants, regardless of adherence or complete
follow-up. In cases where outcome data for excluded participants
have not been published, we will contact the authors of the
trial and request their original data. We will gather information
on non-completing participants, including the time and reason
for dropping out, as described by the trial authors, and record
this on the information extraction form. Where possible, we will
incorporate multiple imputation into the analysis (Jakobsen 2017).
In addition, we will perform 'worst-best case scenario' and 'best-
worst case scenario' analyses for participants lost to follow-up as
sensitivity analyses (CHBG Information for authors). A best-worst
case analysis is where it is assumed that none of the dropouts lost
from the experimental arm, but all of the dropouts lost from the
control arm, experienced the outcome. A worst-best case analysis
is where it is assumed that all dropouts lost from the experimental
arm, but none from the control arm experienced the outcome. Both
types of analysis are based on all randomised participants.
Assessment of heterogeneity
We will assess statistical heterogeneity, which is the presence and
extent of between-study variation (Higgins 2021d Box 10.10.a) using
the Chi2 test. Where the P value is less than 0.1, we will assume
there is significant heterogeneity, and quantify heterogeneity using
the I2 statistic (DerSimonian 1986; Higgins 2002). If intervention
trials are combined, errors may arise during the assessment
of heterogeneity due to diKerences in units of analysis (e.g.
trials involving cluster randomisation may diKer in between-
study heterogeneity compared to trials in which individuals are
randomised). Although this possibility is largely unexplored, the
need to distinguish between the two types of randomised trial
has been highlighted (Nyström 2002). To address this, we will use
a fixed-eKect analysis of comparisons within a trial and then a
random-eKect analysis between trials.
Methodological heterogeneity, due to diKerences in how the
individual trials are implemented, and clinical heterogeneity,
due to diKerences in participant and intervention characteristics,
contribute to the presence and magnitude of statistical
Modified dietary fat intake for treatment of gallstone disease (Protocol)









Cochrane Database of Systematic Reviews
heterogeneity (Higgins 2003). We will investigate these types of
heterogeneity using subgroup analysis.
Assessment of reporting biases
If at least ten trials are found, we will assess publication bias in
terms of treatment eKect against trial size by developing a funnel
plot using Review Manager Web (RevMan web 2020). We will stratify
the funnel plots by risk of bias if we have at least 10 trials for each
level of bias (Sterne 2019).
Data synthesis
Meta-analysis
We intend to undertake meta-analysis and present the findings
according to Cochrane recommendations (Deeks 2021; Higgins
2021a). We will combine data from trials with similar populations,
interventions, comparisons, and outcomes. If trials use diKerent
scales to measure the same outcome, we will present the
standardised mean diKerence. This measure expresses the size
of the intervention eKect in each study relative to the variability
observed in that study. We will calculate P values for all
comparisons where this is possible. We will undertake intention-
to-treat analysis wherever possible, so that all randomised
participants are included (Jakobsen 2017). Where this is not
possible, we will carry out an analysis of available participant cases.
If we include a small number of trials, or if the number of
participants is small, we will use the Mantel-Haenszel method for
pooling dichotomous data, as this assumes a fixed-eKect meta-
analysis and is considered an appropriate method (Mantel 1959;
Deeks 2021). For continuous data, we will use standardised or mean
diKerences to pool results. If there is no heterogeneity between
study findings, we will synthesise and analyse data using a fixed-
eKect model meta-analysis (DeMets 1987). If this is not possible, we
will use the random-eKects model (DerSimonian 1986).
If data from included studies preclude meta-analysis, we will
undertake one of the following: we will calculate the eKect estimate
and measure precision from the available statistics if possible
(Higgins 2021e); or we will calculate the eKect estimate and
measure of precision for the same eKect measure from the available
statistics (Higgins 2021e); or we will transform eKect measures (e.g.
convert standardised mean diKerences to an odds ratio; (Deeks
2021)). If none of these are possible, we will tabulate and visually
display the results (McKenzie 2021), and will follow the SWiM
guidelines for systematic reviews without meta-analysis (Campbell
2020).
Subgroup analysis and investigation of heterogeneity
Where there are suKicient trials, we will investigate clinical
heterogeneity by inspection of the funnel plot(s) (Sterne 2001).
We will use a formal statistical test to examine diKerences
among subgroups (Borenstein 2013). This procedure tests for
heterogeneity across subgroup results. If there are suKicient data,
and irrespective of the presence of any heterogeneity, we plan to
perform subgroup analyses. These will include the following.
• Trials at low risk of bias or at low or some concern compared to
trials at high risk of bias (because trials at high risk of bias may
overestimate beneficial intervention eKects or underestimate
harmful intervention eKects; (Savović 2018)).
• Trials with for-profit support compared to trials without for-
profit support (because trials with for-profit support may
overestimate beneficial intervention eKects or underestimate
harmful intervention eKects; (Lundh 2018)).
• Trials with participants with acute compared to chronic
gallstone disease (because diKerences in onset of the condition
may impact on ability to collect dietary data; (Mou 2019)).
• Trials with participants with high body mass index compared to
low body mass index (because body mass index is a measure of
obesity and obesity is associated with higher risk of gallstone
disease; (Stinton 2010)).
• Trials with participants who are malnourished compared to
those who are adequately nourished or over nourished (because
people who are malnourished are at higher risk of an inadequate
intake associated with a low fat diet; (Madden 2014)).
• Trials with participants with diabetes compared to participants
with normoglycaemia (because people with diabetes have a
higher risk of gallstone disease; (Aune 2016)).
• Trials with participants with gallstones composed of cholesterol
compared to participants with gallstones composed of pigment
(because of diKerences in pathogenesis; (Jones 2020)).
We will undertake analyses separately if trials present data in
diKerent units which we cannot convert to a common format (e.g.
grams of dietary fat and % dietary energy from fat).
We will specifically examine the degree of heterogeneity we
observe in the results with the I2 statistic, using the guideline that
an I2 statistic value of 50% or more indicates a substantial level of
heterogeneity (Higgins 2002; Higgins 2003).
We will use subgroup analysis to examine apparent methodological
heterogeneity (Deeks 2021; Schünemann 2021).
Sensitivity analysis
If we identify a suKicient number of randomised trials, we will
perform sensitivity analyses to examine the impact of the following
factors on eKect size:
• excluding trials at high risk of bias;
• size of trials (e.g. large trials);
• trials identified using the following filters: diagnostic criteria;
language of publication; source of funding (industry compared
to other);
• the impact of participant loss to follow-up by conducting 'worst-
best case scenario' and 'best-worse case scenario' analyses.
Trial Sequential Analysis
We will use Trial Sequential Analysis (TSA) to control the risk of
producing random errors due to sparse data and multiple testing
of accumulating data (Brok 2008; Wetterslev 2008; Brok 2009;
Thorlund 2009; Thorlund 2017; Wetterslev 2017). We will compare
our GRADE assessment of imprecision with the TSA assessment
of imprecision. We will calculate the required information size
(that is, the number of participants needed in a meta-analysis to
detect or reject a certain intervention eKect) in order to control
for random errors (Wetterslev 2008; Wetterslev 2009). For each
TSA performed, we will calculate a diversity-adjusted required
information size, based on the intervention eKect suggested by
trials at low risk of bias and an intervention eKect of 20% risk
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reduction, a type I error risk of 2.0% (the conventional value of 5.0%
divided by 3, rounded, because of our three primary outcomes),
and a type II error risk of 10% (Wetterslev 2009). We will perform
the diversity adjustment using the observed diversity adjustment
factor 1/(1 - D2), the heterogeneity estimated by D2 among all
trials, and with an assumed final diversity of 50% (Wetterslev
2009). For continuous outcomes we will use a minimal relevant
diKerence equal to SD/2, where SD is the standard deviation of the
control group; type I error risk of 2.0%; and a type II error risk of
10%. We will perform meta-analyses sequentially by introducing
trials in chronological order (Wetterslev 2017). We will use trial
sequential monitoring boundaries to obtain adjusted confidence
intervals when the diversity-adjusted required information size and
the corresponding number of required trials for the meta-analysis
have not been reached (Lan 1983).
If the cumulative Z-value in a particular TSA does not cross
the monitoring boundaries for benefit, harm, or futility, we will
downgrade our assessment of imprecision in GRADE (see below)
by two levels if the accrued number of participants is below 50%
of the diversity-adjusted required information size (DARIS), and by
one level if it is between 50% and 100% of the DARIS (Jakobsen
2014). We will not downgrade for imprecision if the cumulative
Z-value reaches or crosses benefit, harm, futility, or the DARIS
(Jakobsen 2014). We will perform TSA with the Trial Sequential
Analysis soIware, version 0.9.5.10 beta (Thorlund 2017; TSA 2017).
Summary of findings and assessment of the certainty of the
evidence
We will use the GRADE approach to present data in summary of
findings tables as follows. We will present comparisons between
the experimental interventions and the control interventions for
each primary outcome in a separate summary of findings table.
• All-cause mortality, at longest follow-up.
• Proportion of participants with serious adverse events at longest
follow-up.
• Health-related quality of life, assessed using validated tests at a
range of follow-ups, including longest follow-up.
We will also provide the maximum follow-up and the range of
follow-up for each of the outcomes.
For each outcome, we will include the following information in each
summary of findings table.
• The assumed risk; a measure of the typical burden of the
outcomes, i.e. the illustrative risk, also called the baseline risk,
baseline score, or control group risk.
• The corresponding risk; a measure of the burden of the
outcomes aIer the intervention is applied, i.e. the risk of
an outcome in treated/exposed people based on the relative
magnitude of an eKect and assumed (baseline) risk.
• The relative eKect; for dichotomous outcomes, the table will
provide the risk ratio, odds ratio, or hazard ratio.
• The number of participants, and the number of trials and their
designs.
• Rating of the overall certainty of evidence for each outcome
(which may vary by outcome).
• Footnotes or explanations, if needed, to provide explanations
about information in the table.
• Comments (if needed).
We will also present the certainty of the evidence for the outcomes
reported in the review by considering the within-study risk of bias
(methodological quality); indirectness of evidence (population,
intervention, control, outcomes); unexplained heterogeneity or
inconsistency of results (including problems with subgroup
analyses); imprecision of the eKect estimate (wide conference
intervals; (Jakobsen 2014); and risk of publication bias (Meader
2014; GRADEpro GDT)). Two reviewers (DT and AMM) will work
independently to define the evidence as 'high', 'moderate', 'low',
or 'very low' certainty. These levels are defined as follows
(Schünemann 2013).
• High: we are very confident that the true eKect lies close to that
of the estimate of the eKect.
• Moderate: we are moderately confident in the eKect estimate.
The true eKect is likely to be close to the estimate of the eKect,
but there is a possibility that it is substantially diKerent.
• Low: our confidence in the eKect estimate is limited. The true
eKect may be substantially diKerent from the estimate of the
eKect.
• Very low: we have very little confidence in the eKect estimate.
The true eKect is likely to be substantially diKerent from the
estimate of eKect.
We will resolve disagreement first by discussion and second, if
required by, a third reviewer (NS or AC).
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Appendix 1. Search strategy
 




Search will be given at
review stage.
(diet* AND fat* AND (restrict* OR modif* or reduc* or low* or high*)) AND
(cholelithiasis or gallstone* or gall-stone* or ((gall or gall bladder or gallblad-
der) and stone*))
Cochrane Central Reg-
ister of Controlled Tri-
als (CENTRAL) in the
Cochrane Library
Latest issue #1 MeSH descriptor: [Nutrition Therapy] explode all trees
#2 MeSH descriptor: [Dietary Fats] explode all trees
#3 MeSH descriptor: [Diet, Fat-Restricted] explode all trees
#4 MeSH descriptor: [Diet, High-Fat] explode all trees
#5 diet* and fat* and (restrict* OR modif* or reduc* or low* or high*)
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Cholelithiasis] explode all trees
#8 cholelithiasis or gallstone* or gall-stone* or ((gall* or gall bladder or gall-
bladder) and stone*)
#9 #7 or #8
#10 #6 and #9
MEDLINE Ovid 1946 to the date of the
search
1. exp Nutrition Therapy/
2. exp Dietary Fats/
3. exp Diet, Fat-Restricted/
4. exp Diet, High-Fat/
5. (diet* and fat* and (restrict* OR modif* or reduc* or low* or high*)).mp.
[mp=title, abstract, original title, name of substance word, subject heading
word, protocol supplementary concept, rare disease supplementary concept,
unique identifier]
6. 1 or 2 or 3 or 4 or 5
7. exp Cholelithiasis/
8. (cholelithiasis or gallstone* or gall-stone* or ((gall or gall bladder or gall-
bladder) and stone*)).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
9. 7 or 8
10. 6 and 9
11. (randomized controlled trial or controlled clinical trial).pt. or clinical trials
as topic.sh. or trial.ti.
12. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, floating sub-
heading word, keyword heading word, organism supplementary concept
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word, protocol supplementary concept word, rare disease supplementary con-
cept word, unique identifier, synonyms]
13. 10 and (11 or 12)
Embase Ovid 1974 to the date of the
search
1. exp diet therapy/
2. exp fat intake/
3. exp lipid diet/
4. (diet* and fat* and (restrict* OR modif* or reduc* or low* or high*)).mp.
[mp=title, abstract, subject headings, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword]
5. 1 or 2 or 3 or 4
6. exp cholelithiasis/
7. (cholelithiasis or gallstone* or gall-stone* or ((gall or gall bladder or gall-
bladder) and stone*)).mp. [mp=title, abstract, subject headings, heading word,
drug trade name, original title, device manufacturer, drug manufacturer, de-
vice trade name, keyword]
8. 6 or 7
9. 5 and 8
10. Randomized controlled trial/ or Controlled clinical trial/ or trial.ti.
11. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract,
heading word, drug trade name, original title, device manufacturer, drug man-
ufacturer, device trade name, keyword, floating subheading word, candidate
term word]





1982 to the date of the
search
(diet$ and fat$ and (restrict$ OR modif$ or reduc$ or low$ or high$)) [Words]
and (cholelithiasis or gallstone* or gall-stone$ or ((gall or gall bladder or gall-
bladder) and stone$)) [Words]
Science Citation In-
dex Expanded (Web of
Science)
1900 to the date of the
search
# 5 #4 AND #3
# 4 TI=(random* or blind* or placebo* or meta-analys* or trial*) OR TS=(ran-
dom* or blind* or placebo* or meta-analys*)
# 3 #2 AND #1
# 2 TS=(cholelithiasis or gallstone* or gall-stone* or ((gall or gall bladder or
gallbladder) and stone*))





1990 to the date of the
search
# 5 #4 AND #3
# 4 TI=(random* or blind* or placebo* or meta-analys* or trial*) OR TS=(ran-
dom* or blind* or placebo* or meta-analys*)
# 3 #2 AND #1
# 2 TS=(cholelithiasis or gallstone* or gall-stone* or ((gall or gall bladder or
gallbladder) and stone*))
  (Continued)
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Cochrane Database of Systematic Reviews
# 1 TS=(diet* and fat* and (restrict* OR modif* or reduc* or low* or high*))
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
3 June 2021 New citation required and major
changes
The whole protocol is updated to conform with recent Cochrane
methodology guidelines.
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